Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- 私人配售完成後，Enlivex 將透過累積 RAIN 代幣，採用全球首個 RAIN 預測市場代幣數碼資產儲備策略。 - RAIN 作為完全去中心化的預測與期權協定，重塑預測市場生態系統，並為鏈上市場創建提供專為透明度、自動化及社區參與而精心打造的強大平台。 - 意大利前總理 Matteo Renzi 先生將於私人配售完成後獲委任加入 Enlivex 董事局。 - Enlivex...
-
- Após o fechamento da colocação privada, a Enlivex adotará a primeira estratégia de tesouro de ativos digitais de token de previsão RAIN do mundo, por meio do acúmulo de token RAIN. - RAIN é um...
-
- Tras el cierre de la colocación privada, Enlivex adoptará la primera estrategia de tesorería de activos digitales basada en mercados de predicción del mundo, mediante la acumulación del token RAIN. ...
-
- Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully...
-
Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
-
Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
-
New York, USA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight CRISPR therapies offer...
-
Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a...
-
Ottawa, Sept. 23, 2025 (GLOBE NEWSWIRE) -- The global systemic inflammatory response syndrome treatment market size reached USD 13.85 billion in 2024. It is projected to rise from USD 14.89 billion...
-
Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month data expected...